[The use of aldosterone antagonists in the cardiovascular diseases].
Trzaska
Emilia
E
Zakład Farmakodynamiki, Warszawski Uniwersytet Medyczny, ul. Krakowskie Przedmieście 26/28, 00-325 Warszawa, Poland. etrzaska@wum.edu.pl
Gumułka
Witold
W
Makulska-Nowak
Helena E
HE
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006332:Cardiomegaly / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D000077545:Eplerenone; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D007703:Peptidyl-Dipeptidase A / Q000627:therapeutic use; D013148:Spironolactone / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone; D007703:Peptidyl-Dipeptidase A